期刊
NATURE REVIEWS CLINICAL ONCOLOGY
卷 15, 期 5, 页码 325-340出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nrclinonc.2018.29
关键词
-
类别
资金
- US National Institutes of Health (NIH) National Cancer Institute [P01 CA080124, R01-CA096915, R01-CA159258, R41-CA213678, R01-CA129371, R01-CA208205, U01-CA 224348]
- Outstanding Investigator Award [R35-CA 1 97743, P50-CA165962]
- German Research Foundation (DFG)
- Solidar-Immun Foundation
- Aid for Cancer Research Foundation
- Tosteson Fund for Medical Discovery (FMD)
- Gates Foundation
- Ludwig Center at Harvard
- Lustgarten Foundation
- National Foundation for Cancer Research
Immunotherapy has emerged as a major therapeutic modality in oncology. Currently, however, the majority of patients with cancer do not derive benefit from these treatments. Vascular abnormalities are a hallmark of most solid tumours and facilitate immune evasion. These abnormalities stem from elevated levels of proangiogenic factors, such as VEGF and angiopoietin 2 (ANG2); judicious use of drugs targeting these molecules can improve therapeutic responsiveness, partially owing to normalization of the abnormal tumour vasculature that can, in turn, increase the infiltration of immune effector cells into tumours and convert the intrinsically immunosuppressive tumour microenvironment (TME) to an immunosupportive one. Immunotherapy relies on the accumulation and activity of immune effector cells within the TME, and immune responses and vascular normalization seem to be reciprocally regulated. Thus, combining antiangiogenic therapies and immunotherapies might increase the effectiveness of immunotherapy and diminish the risk of immune-related adverse effects. In this Perspective, we outline the roles of VEGF and ANG2 in tumour immune evasion and progression, and discuss the evidence indicating that antiangiogenic agents can normalize the TME. We also suggest ways that antiangiogenic agents can be combined with immune-checkpoint inhibitors to potentially improve patient outcomes, and highlight avenues of future research.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据